Oppenheimer John J.
Transaction: 08/12/2025
OTHER
Change
0
Price
Not reported
Filing
09/25/2025
Type
OTHER
bioAffinity Technologies, Inc.
BIAF • Medical - Diagnostics & Research
$15.27
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$79.81M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 381.7%Manageable debt level · 0.16Healthy liquidity · 2.6Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 21, 2026, 12:20 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$15.27
Change0.00%
Shares Out5.23M
Market Cap$79.81M
Enterprise Value$78.82M
52W Range0.33 - 13.50
Beta-1.05
P/E-5.26
P/S13.53
P/B21.18
P/FCF-6.90
EV/Sales13.36
Price$15.27
Change0.00%
Shares Out5.23M
Market Cap$79.81M
Enterprise Value$78.82M
52W Range0.33 - 13.50
Beta-1.05
P/E-5.26
P/S13.53
P/B21.18
P/FCF-6.90
EV/Sales13.36
EV/EBITDA-5.36
EV/FCF-6.82
Earnings Yield-19.03%
FCF Yield-14.48%
Dividend Yield0.00%
Gross Margin23.21%
Oper. Margin-171.58%
Profit Margin-2.42%
Debt/Eq0.16
Current Ratio2.60
Quick Ratio2.58
Volume3.34M
Avg Volume399.51K
EPS Surprise1.59
Investment DNA
How strong this company looks for long-term investors
56
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Positive revenue growth · 381.7%Manageable debt level · 0.16Healthy liquidity · 2.6Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 1 analyst votes · 2026-09-05
50/100
Neutral
Bullish
0
Hold
1
Bearish
0
Insider Transactions
Recent executive and insider activity
Rios Roberto
Transaction: 08/12/2025
OTHER
Change
0
Price
Not reported
Filing
09/25/2025
Type
OTHER
Zannes Timothy P
Transaction: 01/10/2025
BUY
Change
+8,641
Price
Not reported
Filing
01/14/2025
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Oppenheimer John J. | OTHER | 0 | Not reported | 08/12/2025 | 09/25/2025 |
| Rios Roberto | OTHER | 0 | Not reported | 08/12/2025 | 09/25/2025 |
| Zannes Timothy P | BUY | +8,641 | Not reported | 01/10/2025 | 01/14/2025 |
| Edwards James Michael | BUY | +6,172 | Not reported | 01/10/2025 | 01/14/2025 |
| Zannes Maria | BUY | +37,037 | Not reported | 01/10/2025 | 01/14/2025 |
| GIRGENTI STEVEN | BUY | +14,814 | Not reported | 01/10/2025 | 01/14/2025 |
| Reveles Xavier Trinidad | BUY | +21,604 | Not reported | 01/10/2025 | 01/14/2025 |
| Edwards James Michael | BUY | +100,000 | Not reported | 11/05/2024 | 11/05/2024 |
| Edwards James Michael | OTHER | 0 | Not reported | 09/16/2024 | 09/20/2024 |
| Edwards James Michael | OTHER | +6,120 | $3.06 | 09/01/2022 | 09/20/2024 |
| Edwards James Michael | OTHER | +5,876 | $3.06 | 09/01/2022 | 09/20/2024 |
| Edwards James Michael | OTHER | +761 | $5.25 | 07/20/2022 | 09/20/2024 |
| KNIGHT PETER S | BUY | +33,784 | Not reported | 07/01/2024 | 07/02/2024 |
| Rubin Gary D | BUY | +33,784 | Not reported | 07/01/2024 | 07/02/2024 |
| Platt Jamie | BUY | +33,784 | Not reported | 07/01/2024 | 07/02/2024 |
| Zannes Maria | BUY | +33,784 | Not reported | 07/01/2024 | 07/02/2024 |
| Joyce Roby | BUY | +33,784 | Not reported | 07/01/2024 | 07/02/2024 |
| Anderson Robert A. | BUY | +33,784 | Not reported | 07/01/2024 | 07/02/2024 |
| GIRGENTI STEVEN | BUY | +33,784 | Not reported | 07/01/2024 | 07/02/2024 |
| DIAMOND STUART | BUY | +33,784 | Not reported | 07/01/2024 | 07/02/2024 |